Find an expert

The molecular evolution of cytochrome P450 Enzymes: biological catalysts of unprecedented versatility.

Cytochrome P450 enzymes (CYPs, P450s) especially those responsible for drug metabolism in humans, are the unifying theme of the research in our lab. These fascinating enzymes are catalysts of exceptional versatility, and functional diversity. In humans they are principally responsible for the clearance of a practically unlimited variety of chemicals from the body, but are also critical in many important physiological processes. In other organisms (plants, animals, bacteria, fungi, almost everything!) they carry out an unprecedented range of functions, such as defense, chemical communication, neural development and even pigmentation. P450s are involved in the biosynthesis of an unequalled range of potent, biologically active natural products in microbes, plants and animals, including many antibiotics, plant and animal hormones, signalling molecules, toxins, flavours and fragrances. We are studying how P450s have evolved to deal with novel substrates by reconstructing ancestral precursors and evolutionary pathways, to answer such questions as how did the koala evolve to live on eucalyptus leaves, a toxic diet for most mammals.

The capabilities of P450s are only just coming to be fully recognized and structural studies on P450s should yield critical insights into how enzyme structure determines function. For example, recently we discovered that P450s are present within cells in the Fe(II) form, a finding that has led to a radical revision of the dogma concerning the P450 catalytic cycle, and has implications for the control of uncoupling of P450 activity in cells. Importantly, the biotechnological potential of P450s remains yet to be exploited. All of the specific research themes detailed below take advantage of our recognized expertise in the expression of recombinant human cytochrome P450 enzymes in bacteria. Our group is interested in finding out how P450s work and how they can be made to work better.

Artificial evolution of P450s for drug development and bioremediation: a way of exploring the sequence space and catalytic potential of P450s. The demonstrated catalytic diversity of P450 enzymes makes them the ideal starting material for engineering sophisticated chemical reagents to catalyse difficult chemical transformations. We are using artificial (or directed) evolution to engineer enzymes that are more efficient, robust and specialized than naturally occurring enzymes with the aim of selecting for properties that are commercially useful in the areas of drug discovery and development and bioremediation of pollutants in the environment. The approach we are using also allows us to explore the essential sequence and structural features that underpin all ~12000 known P450s so as to determine how they work.

Synthetic biology of enzymes for clean, green, solar-powered chemistry in drug development, bioremediation and biosensors. We have identified ancestral enzymes that are extremely thermostable compared to their modern counterparts, making them potentially very useful in industry, since they can withstand long incubations at elevated temperatures. They can be used as ‘off the shelf’ reagents to catalyse useful chemistry, such as in in drug discovery and development, fine chemicals synthesis, and cleaning up the environment. Working with drug companies, we are exploring how they can be best deployed in chemical processes and what structural features make them efficient, robust and specialized. We are also immobilizing P450s in virus-like-particles as ‘designer’ reagents that can be recovered from reactions and reused. To make such processes cheaper and more sustainable, we are using photosynthesis to power P450 reactions for clean, green biocatalysis in microalgae.

Biosketch:

After graduating from UQ with first class Honours in Biochemistry, Elizabeth took up a Royal Commission for the Exhibition of 1851 Overseas Scholarship to pursue doctoral work at Oxford University then undertook postdoctoral work at the Center in Molecular Toxicology and Department of Biochemistry at Vanderbilt University School of Medicine with Prof. F.P. Guengerich. She returned to UQ in 1993 to take up a position in Pharmacology and joined the School of Chemistry and Molecular Biosciences in 2009 as a Professor of Biochemistry.

Present Position

I am an ARC Future Fellow at the Centre for Advanced Imaging and associated with the University of Oxford as a Senior Visiting Research Fellow.

Previous Positions

• August 2007 to March 2013: Scientific Coordinator and Applications manager of the Centre of Advanced Electron Spin Resonance (CAESR) at the Oxford University, UK.
• 2002-July 2007: Project leader (“Ober-assistent”) in the Physical Chemistry Department at the Swiss Federal Institute of Technology (ETH), Zürich. I was a project leader in the electron paramagnetic resonance group of Prof. Arthur Schweiger.
• 1999-2002: Postdoctoral position at ETH, Zurich. In the group of Prof. Arthur Schweiger I used CW and pulse EPR as a tool to investigate the geometric and electronic properties of transition metal complexes.
• 1996-1999: Doctor of Philosophy from the Chemistry Department of the University of Newcastle, Australia, Advanced Coal Characterization by Nuclear Magnetic Resonance. The project was funded by the Collaborative Research Centre for Black Coal Utilization and I was supervised by the University of Newcastle (Prof. Marcel Maeder), BHP Research Melbourne (Dr. Brian Smith) and Callcott Coal Consulting (Dr. Tom Callcott).
• 1995: Researcher at BHP Central Research Laboratories, Newcastle, Australia. I developed experimental techniques to measure the conductivity and the permeability of coal as it pertains to coke ovens.
• 1992-1995: Researcher at Oakbridge Research Center, Newcastle, Australia. I worked on high temperature Nuclear Magnetic Resonance (NMR) for coal characterization (for my Bachelor of Science Honors thesis). This was a collaboration between the CSIRO Coal and Energy Division (North Ryde, Sydney), Oakbridge Research Centre and the University of Newcastle.

Keywords

structural biology · protein interactions · metalloenzymes · metal complexes · electron transfer · Iron sulphur clusters · pulse EPR · CW EPR · DEER · PELDOR ·HYSCORE · ENDOR · ESEEM · density functional theory · molecular dynamics

Organic Chemistry

PhD

Professor Elizabeth Krenske leads a computational chemistry laboratory that specialises in understanding molecular behaviour. Her laboratory has a particular focus on the study of chemical reaction mechanisms, including the computational prediction of reaction outcomes. Prof. Krenske obtained her PhD in synthetic main-group chemistry at The Australian National University's Research School of Chemistry, where she worked with Professor Bruce Wild. After two years of postdoctoral research at the ANU she was awarded a Fulbright Postdoctoral Scholarship and spent two years at the University of California, Los Angeles, working in the field of theoretical and computational chemistry with Professor Kendall Houk. She returned to Australia in 2009 as an ARC Australian Postdoctoral Fellow at the University of Melbourne, and moved to The University of Queensland in 2012 as an ARC Future Fellow. She is currently a Professor in the UQ School of Chemistry and Molecular Biosciences.

Prof. Krenske is a Fellow of the Royal Australian Chemical Institute, Fellow of the Royal Society of Chemistry, Fellow of the Higher Education Academy and former Associate Editor of the RSC journal Organic & Biomolecular Chemistry.

A/Prof Landsberg's undergraudate and Honours studies, majoring in Chemistry, were completed at Central Queensland University and the CSIRO (JM Rendel laboratories) before he moved to the University of Queensland to study a PhD in Biochemistry (awarded 2003). He then moved to a postdoctoral position at the Institute for Molecular Bioscience, spending time as a Visiting Scientist at Harvard Medical School (2008) and securing promotion to Senior Research Officer upon his return to IMB in 2009. He additioanlly spent time as a Visiting Scientist at the Victor Chang Cardiac Research Institute in 2010 and 2011.

In 2016, he joined UQ's School of Chemistry and Molecular Biosciences as a Group Leader in Cryo-EM and Macromolecular Structure and Senior Lecturer in Biochemistry and Biophysics, where he was promoted to Associate Professor in 2019. He has secured >$13.5M in competitive research funding since 2012, including major grants from the Australian Research Council and National Health and Medical Research Council. He his research has been presented at over 70 national and international conferences and research institutions.

Biography

Jeffrey Mak (PhD) is an organic chemist at the Institute for Molecular Bioscience. His publications cover a range of disciplines such as biological and medicinal chemistry, total synthesis, and physical organic chemistry. Dr Mak was selected as a Rising Star of Chemistry by the Australian Journal of Chemistry (2022).

Jeffrey Mak was awarded the Harriett Marks Bursary and a UQ University Medal before undertaking doctorate studies in natural product total synthesis with Prof. Craig Williams. This culminated in the first total synthesis of two caged diterpenes, (−)-neovibsanin G and (−)-14-epi-neovibsanin G. Next, he joined Prof. David Fairlie's group at the Institute for Molecular Bioscience. He is currently active in the fields of chemical biology and drug development. He is recognised for his development of ligands that modulate mucosal associated invariant T (MAIT) cells, which are a newly characterised subset of immune cells important in antibacterial defence (Accounts of Chemical Research, 2021). In 2014, he was part of an Australian team that discovered the identity of the ligands that activate MAIT cells, as published in Nature, playing a key role in the chemical synthesis and characterisation of the unstable and structurally unprecedented ligands (Nature Communications, 2017). He was selected as a CAS SciFinder Future Leader by the Chemical Abstract Service (a division of the American Chemical Society, 2017). In 2018, Dr Mak was chief investigator on a UQ Early Career Researcher Grant for developing new drug leads that target MAIT cells. Other recent awards include RSC Twitter Poster Conference (Chemical Biology) 1st Prize (2018), and a CASS Travel Award (2018).

Dr Mak has lectured in the undergraduate course Advanced Organic Chemistry (CHEM3001, 2017-2023). He has also served as a member of the UQ Cultural Inclusion Council, and as an ACS Wikipedia Fellow to systematically improve the chemistry and scientific content on Wikipedia (2018).

Student projects

Projects in medicinal chemistry, synthesis, and chemical biology are available (depending on lab space) for enthusiastic organic chemistry students at all levels (PhD, Masters, Honours, Undergraduate). These include the design and synthesis of:

1. Stable analogues of immunostimulating bacterial ligands towards vaccines and anti-cancer immunotherapies
2. Chemical biology tools for exploring MAIT cell activation
3. Highly selective histone deacetylase (HDAC) inhibitors as new drug leads

Previous student publications:

1. Mak JYW* et al. (2024) Potent Immunomodulators Developed from an Unstable Bacterial Metabolite of Vitamin B2 Biosynthesis. Angewandte Chemie, e202400632.
2. Mak JYW et al. (2021) HDAC7 inhibition by phenacetyl and phenylbenzoyl hydroxamates. Journal of Medicinal Chemistry, 64 (4), 2186-2204.
3. Awad W, Ler GJM et al. (2020) The molecular basis underpinning the potency and specificity of MAIT cell antigens. Nature Immunology, 21 (4), 400-411.
4. Ler GJM, Xu W, Mak JYW, Liu L et al. (2019) Computer modelling and synthesis of deoxy and monohydroxy analogues of a ribitylaminouracil bacterial metabolite that potently activates human T cells. Chemistry – A European Journal, 25 (68), 15594-15608.

Jared is a proud Yuwi man, pharmacist and early-career researcher with interests spanning from culturally safe and effective pharmacy practice through to new technologies for pharmaceutical development and delivery. After graduating from UQ with a Bachelor of Pharmacy (Honours) in 2012, he worked as a community pharmacist before returning to undertake a PhD in pharmaceutical sciences, focusing on discovering new drugs for Alzheimer’s disease. Throughout his PhD, Jared developed an interest in teaching and tutored for many pharmacy courses. Ultimately this led to his current role as a Lecturer with UQ School of Pharmacy upon finishing his PhD in 2021. Jared also works as a clinical and research pharmacist with the Institute of Urban Indigenous Health (IUIH).

Professor Mobli is a structural biologist and a group leader at the University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN). He is well known internationally for his contributions to the basic theory of multidimensional nuclear magnetic resonance and its applications to resolving the molecular structure of peptides and proteins, as well as studying their physiochemical properties and function. Mehdi's contributions to the field has been recognised by being appointed an Executive Editor of the AMPERE society's journal "Magnetic Resonance", and to the advisory board of the international Biological Magnetic Resonance Data Bank (BMRB) as well as serving on the board of directors of the Australia and New Zealand Society for Magnetic Resonance (ANZMAG). He is a former ARC Future Fellow and recipient of the ASBMB MERCK medal, the Australia Peptide Society's Tregear Award, the ANZMAG Sir Paul Callaghan medal and the Lorne Proteins Young Investigator Award (now Robin Anders Award).

Prof. Mobli's research group focuses on characterising the structure and function of receptors involved in neuronal signalling, with a particular focus on developing new approaches for the discovery and characterisation of modulators of these receptors through innovations in bioinformatics, biochemistry and and biophysics. This work has led to publication of more than 100 research articles attracting over 6,000 citations.

Dr Moyle’s laboratory (www.moylelab.com) uses cutting edge technologies for the synthesis of peptides, protein expression, and protein semi-synthesis to gain insights into the functional roles played by various biochemical pathways, to engineer better protein and peptide therapeutics, and to improve the delivery characteristics of various therapeutic molecules. Specific current areas of interest are detailed below:

1. Subunit Vaccine Development: methods to develop improved vaccines through the combination of recombinant and synthetic approaches to improve immunopotency and tailor immune responses (links to reseach articles on semisynthetic vaccines and peptide vaccines; reviews on vaccine development).
2. Delivery Systems for Nucleic Acid-Based Molecules: multi-component synthetic and recombinant approaches to improve the cellular uptake, and targeted delivery of various oligonucleotide molecules (e.g. siRNA, mRNA, pDNA and CRISPR-Cas9) as an exciting approach to treat or prevent various diseases (links to research articles and reviews).
3. Deciphering the Roles of Post-Translational Modifications: The combination of peptide synthesis and protein semisynthesis to enable the production of large amounts of site-specifically modified species, that can be used to deconvolute the roles played by various post-translational modifications (links to research articles).
4. Peptide/Protein Drugs and Delivery: The study of methods to improve the delivery characteristics of peptide/protein drugs (e.g. poor oral absorption, instability to chemical/enzymatic degradation, and the inability to reach their site/s of action) through chemical engineering approaches.
5. New Approaches for Superbugs: the development of antivirulence approaches, and formulations (e.g. various types of nanoparticles - silver, protein, mesoporous silica), which reduce the ability for microbes to cause disease, and make them more readily treated with antimicrobials, by providing access to synergistic combinations, and reducing the risk of antimicrobial resistance.

Information for Potential Students:

The Moyle lab considers applications from potential students and postdoctoral fellows with an interest in: i) infection control (including subunit vaccine and antimicrobial development); ii) delivery systems for peptide therapeutics; iii) targeted delivery systems; iv) studying the function of posttranslational modifications; and v) delivery systems for nucleic acid-based therapeutics (e.g. siRNA, shRNA, miRNA, mRNA, pDNA and CRISPR-Cas9). If you are interested in working in any of these areas please feel free to contact Dr Moyle (p.moyle@uq.edu.au). Please ensure that you supply an up to date CV; describe why you would like to work in the Moyle lab; provide a listing of publications (preferably with impact factors and citation counts); and indicate what skills you would bring to the lab. Detailed information on our laboratory is available at www.moylelab.com. Preference will be given to students and postdoctoral fellows who have their own funding.

Dr Moyle Biosketch:

Dr Moyle (H-index 30, >2600 citations; >95 publications; 13/8/2024; Google Scholar, ORCID, ResearcherID, and Publons profiles) received a PhD (Dec 2006) and a Bachelor of Pharmacy (Hons I) (Dec 2001) from The University of Queensland (UQ); graduated from the Pharmaceutical Society of Australia pre-registration pharmacist-training course (Nov 2002); and is registered with the Pharmacy Board of Australia. He currently works as an Associate Professor in the UQ School of Pharmacy, where he has been based since 2014.

Dr Moyle works in the fields of medicinal chemistry, chemical biology, and drug formulation, investigating subunit vaccine development, outcomes associated with histone post-translational modifications, and methods to improve the delivery characteristics of oligonucleotide (e.g. siRNA and pDNA), peptide, and protein therapeutics. During his PhD, Dr Moyle developed methods that enabled the synthesis of pure, lipid adjuvanted peptide vaccines, using advanced chemical ligation techniques. In addition, the conjugation of mannose to combined prophylactic/therapeutic human papillomavirus type-16 vaccines, to target dendritic cells, was demonstrated to significantly improve vaccine anti-tumour activity. This work, conducted with leading researchers at the QIMR Berghofer Medical Research Institute (Prof Michael Good & Dr Colleen Olive), established Dr Moyle’s national and international profile in the field of vaccine development, resulting in 11 peer reviewed papers, including top journals in the field (J Med Chem; J Org Chem), as well as 6 review articles and 2 invited book chapters.

Dr Moyle undertook his postdoctoral training in the laboratory of one of the world’s premier chemical biologists, Professor Tom Muir (the Rockefeller University, NY, USA; now at Princeton University, NJ, USA). During this time he developed an extensive knowledge of techniques for protein expression, bioconjugation, bioassays, and proteomics, which represent an essential skill set required for this proposal. As part of this work, Dr Moyle developed novel synthetic routes to generate site-specific ADP-ribose conjugated peptides and proteins. This research was hailed as a major breakthrough in the field, leading to several collaborations, and an exemplary publication in the prestigious chemistry journal JACS. This vast body of work identified the enzyme (PARP10) responsible for mono-ADP-ribosylation of histone H2B, and demonstrated interactions between this modification and several proteins, including BAL, which is associated with B cell lymphomas. In addition, a number of robust chemical methods were developed to enable the synthesis of a complete library of methyl-arginine containing histones, which were incorporated into synthetic chemically-defined chromatin to investigate the site-specific effects of arginine methylation on histone acetylation. This work led to a collaboration with colleagues at Rockefeller to investigate the effects of histone arginine methylation on transcription.

Teaching:

Dr Moyle teaches into the following subjects in the UQ School of Pharmacy.

• PHRM3011 (Quality Use of Medicines) - course coordinator
• PHRM4021 (Integrated Pharmaceutical Development)
• PHRM3021 (Dosage Form Design)
• PHRM2040 (Drug Discovery)

Awards:

2016 - Health and Behavioural Sciences (HABS) faculty commendation for Early Career Citations for Outstanding Contributions to Student Learning (ECCOSL)

2015 - ChemMedChem top 10 cited article of 2013 (link)

2014 - Highest ranked NHMRC development grant (2013; APP1074899)

2013 - Institute for Molecular Biology (IMB) Division of Chemistry and Structural Biology Prize

Associate Professor Muttenthaler is a medicinal chemist working at the interface of chemistry and biology with a strong passion for translational research. His research focuses on bioactive peptides and exploring Nature's biodiversity to develop advanced molecular tools, diagnostics, and therapeutics. His background in drug discovery and development, as well as his interdisciplinary training in the fields of chemistry, molecular biology and pharmacology, assist him in characterising these often highly potent and selective compounds to study their interactions with human physiology for medical innovations in pain, cancer, gut disorders and neurological diseases.

Megan O’Mara is a Professor and Group Leader at the Australian Institute for Bioengineering and Nanotechnology (AIBN), UQ. Her group uses multiscale modelling techniques to understand how changes in the biochemical environment of the cell membranes alters membrane properties and modulates the function of membrane proteins. She has research interests in multidrug resistance, computational drug design and delivery, biopolymers, and personalized medicine. Megan completed her PhD in biophysics at the Australian National University in 2005 before moving to the University of Calgary, Canada, to take up a Canadian Institutes of Health Research Postdoctoral Fellowship. In 2009, she returned to Australia to join University of Queensland’s School of Chemistry and Molecular Biosciences as a UQ Postdoctoral Fellow, before commencing an ARC DECRA in 2012 where she continued her computational work on membrane protein dynamics. In 2015, Megan joined the Research School of Chemistry, Australian National University in 2015 as Rita Cornforth Fellow and Senior Lecturer. In 2019 she was promoted to Associate Professor and was Associate Director (Education) of the Research School of Chemistry ANU in 2019-2021. In April 2022 she relocated to AIBN.

Harendra's research interests are in the area of synthetic pharmaceutical chemistry, pharmaceutics as applied to nano-carriers, and advanced non-viral drug/gene delivery system design, synthesis and evaluation. His team at PACE have been instrumental in developing highly versatile micro- & nanobubble formulations, which when used in-conjuction with ultrasound, pave the way for improved rates of 'on-demand' drug delivery and release in target tissue. Harendra also has a keen interest in developing bioresponsive drug/gene delivery systems with current engagement with pharma partners, globally, to commercialise his platforms. Separately, Dr Parekh has been developing a program to reformulate TCMs, in collaboration with researchers at a leading Chinese research institute; the outcomes of this work was aired across Asia in a BBC World News story, and showcased (TV & radio) by the Australian Academy of Science, National Touring Series.

BScPharm(Hon I), PhD (Nottingham)

Harendra completed his BSc in pharmacy (UK) and registered as a Pharmacist in 1998. He went onto undertake his PhD in Medicinal Chemistry at the University of Nottingham in the same year. Under the supervision of Dr B. Kellam and Dr. S. R. Chhabra he investigated the development of novel linkers for solid phase peptide and glycopeptide synthesis. Harendra was awarded his PhD in 2002, and after a short time working in community pharmacy in the UK relocated to Australia and took up a position as research officer in the School of Chemistry at UQ. He continues to be a member of the Royal Pharmaceutical Society of GB and is also registered with the AHPRA (pharmacist) in QLD.

During his post-doctoral tenure he explored the area of non-viral gene delivery via chemical synthesis of novel dendrimeric systems. Emphasis was on the treatment of age-related macular degeneration and in 2004 he received Uniquest's Trailblazer Prize for commercialisation potential. In May 2005 Dr Parekh was appointed Lecturer within the School of Pharmacy, and promoted to Senior Lecturer in 2011. He also holds adjunct positions at Manipal University (India), and the National University of Singapore's Nanoscience and Nanotechnology Institute (NNI).

I am a Principal Investigator (PI) and a senior research officer (SRO) at Mater research – UQ with excellent clinical and research laboratory skills and expertise in conducting and analyzing laboratory assays and resolving complex research and clinical laboratory problems. I can describe myself as determined, reliable, studious, conscientious, attentive, industrious, diligent, and focused on the timely, quality completion of all lab procedures. I am able to work well under pressure and time constraints within high-volume environments both independently and in collaboration within a team. I am also a highly self-motivated and career-oriented individual with a genuine interest in addressing cancer molecular mechanisms with the goal of developing novel cancer therapeutics and immunotherapy focusing on tumor microenvironment, immunoregulation and signaling pathways in cancer and metastasis.

Dr Rosengren is an Associate Professor at the School of Biomedical Sciences, University of Queensland. He completed his PhD, which focused on structure-activity relationships of antimicrobial peptides, under the supervision of Professor David Craik at the Institute for Molecular Bioscience, UQ, in 2003. After two years of post-doctoral work at IMB he moved to Sweden in 2005 to take up a position as Assistant Professor at Linnaeus University, Kalmar. During 2008-2009 he held a joint appointment between Linnaeus University and Uppsala University. In 2009 he was awarded the Swedish “Docent” title before returning to University of Queensland as a Senior Research Officer, funded by an NHMRC Career Development Award and an ARC Future Fellowship. Dr Rosengren’s research focuses on structure activity relationships of bioactive peptides, in particular peptide hormones and the use of NMR spectroscopy in the design of novel peptide drug leads.

Dr Ben Ross is a chemist with interests in medicinal chemistry, computer-aided drug design, virtual screening, synthetic chemistry, enzyme inhibitors, ion channel modulators, antivirals, amyloid diseases, neurodegenerative diseases, and cancer.

Follow Dr Ben Ross and his team on Twitter: @RossChemLab ||| Google Scholar: Benjamin P. Ross ||| ResearcherID: A-9573-2012 ||| ORCID: 0000-0002-1899-8484 ||| Scopus Author ID:7401608823 ||| Group Web Page: www.drbenross.com

Research Interests

The main focus of Dr Ben Ross's research is the application of computer-aided drug design and synthetic chemistry to create new drug candidates for cancer, viral infections, and neurodegenerative diseases such as Alzheimer’s disease. His team's novel molecules are evaluated using a variety of biochemical, biophysical, and cell-based screening assays, as well as animal models of disease, both within their lab and in partnership with local and international collaborators. Consideration of drug-likeness is an integral part of the design process, since good ADMET properties are crucial for their molecules to reach the clinic.

Biography

Ben Ross graduated with a First-Class Honours Degree in Chemistry (1999) and then moved to the UQ School of Pharmacy where he gained a Doctorate in the field of Medicinal Chemistry (2004). He worked in the School of Molecular and Microbial Sciences as a Postdoctoral Research Fellow with Dr Ross McGeary for two years (2004-2006) during which he completed the synthesis of a variety of biologically useful molecules. In June 2006 Ben was appointed to a Lectureship within the UQ School of Pharmacy. In the first half of 2012 he was a Guest Researcher in the Department of Biochemistry and Structural Biology, Lund University, Sweden. In 2013 Ben was promoted to Senior Lecturer at UQ. A general theme of his research is medicinal chemistry, specifically the application of synthetic chemistry and molecular modeling to discover novel molecules with application as drugs or tools for research. Ben's team has published extensively in journals having a moderate-to-high impact factor in their specialised area of research (e.g. Journal of Medicinal Chemistry, Nanoscale, Food Chemistry).

Selected Primary Research Articles

Bifunctional Succinylated ε-Polylysine Coated Mesoporous Silica Nanoparticles for pH-Responsive and Intracellular Drug Delivery Targeting the Colon. C.T.H. Nguyen, R.I. Webb, L.K. Lambert, E. Strounina, E.C. Lee, M.-O. Parat, M.A. McGuckin, A. Popat, P.J. Cabot, B.P. Ross*. ACS Applied Materials & Interfaces 2017, 9, 9470-9483. doi:10.1021/acsami.7b00411 (2016 JIF 7.5, Quartile 1)

Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening. S.N. Dighe, G.S. Deora, E. De la Mora, F. Nachon, S. Chan, M.-O. Parat, X. Brazzolotto*, B.P. Ross*. Journal of Medicinal Chemistry 2016, 59, 7683-7689. doi:10.1021/acs.jmedchem.6b00356 (Featured on the front cover of the journal: http://pubs.acs.org/toc/jmcmar/59/16) (2016 JIF 6.3, Quartile 1)

GAG mimetic functionalised solid and mesoporous silica nanoparticles as viral entry inhibitors of herpes simplex type 1 and type 2 viruses. E.C. Lee, N. Davis-Poynter*, C.T.H. Nguyen, A.A. Peters, G.R. Monteith, E. Strouina, A. Popat*, B.P. Ross*. Nanoscale 2016, 8, 16192-16196. doi:10.1039/C6NR03878F (2016 JIF 7.4, Quartile 1)

Metal chelation, radical scavenging and inhibition of Aβ42 fibrillation by food constituents in relation to Alzheimer’s disease. S. Chan, S. Kantham, V.M. Rao, M.K. Palanivelu, H.L. Pham, P.N. Shaw, R.P. McGeary, B.P. Ross*. Food Chemistry 2016, 199, 185-194. doi:10.1016/j.foodchem.2015.11.118 (2016 JIF 4.5, Quartile 1)

"Click" Assembly of Glycoclusters and Discovery of a Trehalose Analogue that Retards Aβ40 Aggregation and Inhibits Aβ40-induced Neurotoxicity. H. Rajaram, M.K. Palanivelu, T.V. Arumugam, V.M. Rao, P.N. Shaw, R.P. McGeary, B.P. Ross*. Bioorganic & Medicinal Chemistry Letters 2014, 24, 4523-4528. doi:10.1016/j.bmcl.2014.07.077 (2014 JIF 2.4, Quartile 3)

Enzyme-Responsive Controlled Release of Covalently Bound Prodrug from Functional Mesoporous Silica Nanospheres. A. Popat, B.P. Ross, J.Liu, S. Jambhrunkar, F. Kleitz*, S.Z. Qiao*. Angewandte Chemie International Edition 2012, 51, 12486-12489. doi:10.1002/anie.201206416 (2010 JIF 13.7, Quartile 1)

PhD vacancies - PhD opportunities

Australian and international students with backgrounds in chemistry, biochemistry, and pharmacy are encouraged to contact Dr Ben Ross to discuss possible Honours or PhD projects and scholarships.

Sources of funding include: UQ Scholarships; NHMRC Postgraduate Scholarships; Endeavour Scholarships and Fellowships; Malaysia Ministry of Higher Education (MOHE) Scholarships; Ministry of Education Saudi Arabia; and the China Scholarship Council (CSC), as well as many other funding schemes. Contact Dr Ben Ross via email to discuss the best strategy to obtain a scholarship.

Teaching and Service Activities

Dr Ben Ross is the Research Higher Degrees Coordinator for the School of Pharmacy, and an Academic Advisor for Year 2 of the BPharm(Hons) program. He also coordinates and teaches within the following undergraduate BPharm(Hons) courses:

PHRM2021 Dosage Form Design A1;

PHRM2022 Dosage Form Design A2;

PHRM2040 Drug Discovery A1;

PHRM2041 Drug Discovery A2 - Course Coordinator;

PHRM3021 Dosage Form Design B1.

I obtained a Diploma in Chemistry from the University of Bern in Switzerland in 1992. Upon receiving the award of an International Postgraduate Research Scholarship (IPRS) I joined The University of Queensland (UQ) in 1993 to carry out research towards a PhD in Biochemistry(supervisors: Assoc. Profs. Peter Nixon and Ron Duggleby). I graduated in 1997 and continued postdoctoral research at UQ under the guidance of Profs John de Jersey, Susan Hamilton and Graeme Hanson. During this period, I was awarded Fellowships from both the Wellcome Trust and UQ. In 2000 I spent several months in the Department of Chemistry at the University of Newcastle-upon-Tyne, England, collaborating with Prof. Geoff Sykes, and later that year I commenced a Senior Postdoctoral Fellowship in the Chemistry Department at Stanford University (advisor: Prof. Edward Solomon). In 2003 I was appointed to a Lectureship in (Bio)Physical Chemistry at UQ. In 2006 I was promoted to Senior Lecturer. Following the award of a UQ Foundation Research Excellence Award (in 2007) I was promoted to Associate Professor (in 2008), and between 2011 and 2013 I was also on a fractional professorial appointment (50%) at Maynooth University, Ireland. From 2013 to 2017 I held a Future Fellowship from the Australian Research Council, and during this period I was promoted to Full Professor at UQ (2015). I also hold affiliate professorships in the Sustainable Minerals Institute and the Australian Institute for Bioengineering and Nanotechnology, both located at UQ.

I have successfully focused my research on the investigation of enzyme-catalysed reactions, their optimisation for applications in biotechnology and the synthesis of small molecules that mimic their structure and catalytic function (i.e. biomimetics). I advanced understanding of the contribution of metals to enzyme-catalysed reactions and employed state-of-the-art technologies (e.g. cryo-EM, ancestral gene reconstruction) to develop enzyme inhibitors as leads for novel biocides (herbicides, fungicides, antibacterial compounds) and engineer enzymes with enhanced catalytic properties for industrial applications in the advanced manufacturing sector (i.e. cell-free enzyme cascades, next-gen fertilisers). My work into enzyme mechanisms, regulation and engineering received international acclaim evidenced by invitations to provide plenary and keynote lectures and review articles in prestigious journals. I have published over 250 peer-reviewed articles, including over 40 papers in the ACS staple (J. Am. Chem. Soc, ACS Catalysis, ACS Sus. Chem. Eng., Inorg. Chem, Chem. Rev., Acc. Chem. Rev.) as well as landmark studies in Nature, Nature Catalysis, Nature Communications and Proc. Natl. Acad. Sci. (USA). For my leadership in enzymology I was awarded a Future Fellowship by the Australian Research Council, a Foundation Research Excellence Award by UQ and, most recently, the prestigious role as Ambassador for the Technical University of Munich (TUM), an honour bestowed upon me also for my leading role in building an extensive network of collaborations between UQ and TUM in the areas of bioengineering and bioeconomy. The network has since evolved into the Global Bioeconomy Alliance.